Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 4/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425828 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL6730565 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL13317630 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL8600119 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL3425832 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL14356311 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL7143032 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL3954465 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL5981862 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| Water SCHEMBL28110031 | 0.98 | SLC6A2 (0.43) | SLC6A2CA1CA2CA9TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605713-B1 | Contacting D-nucleic acids with a racemic mixture of the target molecule and allow for binding; producing L-nucleic acids; in vitro selection of DNA/RNA with high binding affinity and stability | FURSTE JENS PETER (DE) | 2003-08-12 | — | — | US | claimed |
| US-20170044102-A1 | New Method for Preparing Isofagomine and Its Derivatives | AMICUS THERAPEUTICS INC (US) | 2017-02-16 | — | — | US | disclosed |
| US-9481700-B2 | Method for preparing isofagomine and its derivatives | AMICUS THERAPEUTICS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| EP-2152265-B1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | AMICUS THERAPEUTICS INC (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20140005372-A1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | AMICUS THERAPEUTICS INC (US) | 2014-01-02 | — | — | US | disclosed |
| US-8487110-B2 | Method for preparing isofagomine and its derivatives | AMICUS THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100160638-A1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | AMICUS THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| EP-2152265-A1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | Amicus Therapeutics, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008144773-A1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | AMICUS THERAPEUTICS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1232166-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | Pharmasset Limited (US) | 2002-08-21 | — | — | EP | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| WO-2001034618-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | PHARMASSET LIMITED (US) | 2001-05-17 | — | — | WO | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0434960-B1 | Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates | PHARMACIA SPA (IT) | 1996-09-18 | — | — | EP | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005372-A1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | ALDOA, FBP1, GALE | SLC6A2 75/4885CA1 3285/4885CA2 4256/4885 |
| US-20100160638-A1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | ALDOA, FBP1, GALE | SLC6A2 75/4885CA1 3285/4885CA2 4256/4885 |
| US-20170044102-A1 | New Method for Preparing Isofagomine and Its Derivatives | ALDOA, FBP1, GALE | SLC6A2 75/4885CA1 3285/4885CA2 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.